Trial Profile
A Phase IIa Trial to Assess the Efficacy and Safety of Recombinant Human Prourokinase in the Treatment of Acute Pulmonary Embolism
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Urokinase (Primary) ; Alteplase
- Indications Pulmonary embolism
- Focus Adverse reactions; Therapeutic Use
- Acronyms ERUPTE
- Sponsors Tasly Pharmaceuticals, Inc.
- 16 Mar 2021 Status changed from recruiting to completed.
- 25 May 2017 Status changed from not yet recruiting to recruiting.
- 13 Apr 2017 New trial record